Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

BACKGROUND: Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Vernieri, Fabrizio, Brunelli, Nicoletta, Messina, Roberta, Costa, Carmelina Maria, Colombo, Bruno, Torelli, Paola, Quintana, Simone, Cevoli, Sabina, Favoni, Valentina, d’Onofrio, Florindo, Egeo, Gabriella, Rao, Renata, Filippi, Massimo, Barbanti, Piero, Altamura, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903705/
https://www.ncbi.nlm.nih.gov/pubmed/34922444
http://dx.doi.org/10.1186/s10194-021-01363-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903705/
https://www.ncbi.nlm.nih.gov/pubmed/34922444
http://dx.doi.org/10.1186/s10194-021-01363-y

Ejemplares similares